Literature DB >> 19622461

Three-times weekly teicoplanin as outpatient treatment of chronic osteoarticular infections.

C Tascini1, E Tagliaferri, A Di Paolo, L Ciofi, M Del Tacca, P Lambelet, F Menichetti.   

Abstract

Treatment of difficult-to-treat infections such as osteomyelitis or infections related to indwelling medical devices requires lengthy antibiotic therapy and adequate surgical debridement. Teicoplanin, a glycopeptide antibiotic with a long half-life, was used three-times weekly in the treatment of these infections. After a period of daily dosing with teicoplanin, patients were treated with an intravenous dose of 12 mg on mondays, wednesdays and fridays. A control group of patients were treated with teicoplanin daily. Teicoplanin levels were measured during the study. Thirty-six patients were enrolled in the study: 14 with vertebral osteomyelitis, 12 with infected orthopedic implants, 7 with osteomyelitis and 3 with arterial prosthetic infections. The duration of treatment ranged from 60 to 360 days. Cure was obtained in 21 (58%) patients and improvement in 15 (42%) patients. Trough and peak serum concentrations in three-time weekly patients were 16.2+/-7.2 mg/l and 58.7+/-14.4 mg/l. In the control group trough and peak serum concentrations were 18.9+/-13.6 mg/l and 52.2+/-27 mg/l. Adverse events occurred in 6 patients: mainly mild liver toxicity. Three times weekly teicoplanin seems to be a valuable option in the treatment of chronic infections.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19622461     DOI: 10.1179/joc.2009.21.4.421

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  2 in total

1.  FDG PET/CT is useful for the interim evaluation of response to therapy in patients affected by haematogenous spondylodiscitis.

Authors:  Cristina Nanni; Luca Boriani; Caterina Salvadori; Eleonora Zamparini; Giada Rorato; Valentina Ambrosini; Alessandro Gasbarrini; Fabio Tumietto; Francesco Cristini; Luigia Scudeller; Stefano Boriani; Pierluigi Viale; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-07-21       Impact factor: 9.236

2.  Evaluation of a thrice weekly administration of teicoplanin in the outpatient setting: a retrospective observational multicentre study.

Authors:  John Asumang; Katie L Heard; Oliver Troise; Sandra Fahmy; Nabeela Mughal; Luke S P Moore; Stephen Hughes
Journal:  JAC Antimicrob Resist       Date:  2021-02-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.